nach oben

Die Dermatologie

Erschienen in:

18.11.2022 | Melanom | Leitthema

Tumorinfiltrierende T-Zellen und natürliche Killerzellen im Melanom

verfasst von: Prof. Dr. Julia K. Tietze

Erschienen in: Die Dermatologie | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Melanom ist ein stark immunogener Tumor mit einer erhöhten Dichte an tumorinfiltrierenden Lymphozyten (TIL). TIL sind eine sehr heterogene Zellpopulation, die unter anderem aus CD8⁺-T-Lymphozyten, CD4⁺-T-Lymphozyten, regulatorischen T‑Zellen, B‑Zellen und natürlichen Killerzellen (NK-Zellen) besteht und sich zwischen einzelnen Melanompatienten deutlich unterscheiden kann. Verteilung, Dichte, Profil sowie der Aktivierungsstatus der melanominfiltrierenden Zellen können stark variieren und die Prognose beeinflussen. Verschiedene Unterpopulationen der CD8⁺-T-Zellen, CD4⁺-T-Zellen und NK-Zellen konnten identifiziert und mit dem Verlauf der Erkrankung sowie dem Ansprechen auf verschiedene Therapien assoziiert werden. Ein besseres Verständnis der Funktionen, des Zusammenwirkens und der Aktivierung der unterschiedlichen Populationen sowie das gezielte Beeinflussen einzelner Untergruppen könnte zu vielversprechenden neuen innovativen Therapieansätzen führen.

Clark WH Jr., From L, Bernardino EA et al (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705–727PubMed

van der Bruggen P, Traversari C, Chomez P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647. https://doi.org/10.1126/science.1840703CrossRefPubMed

Vinay DS, Ryan EP, Pawelec G et al (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35:S185–S198. https://doi.org/10.1016/j.semcancer.2015.03.004CrossRefPubMed

Morrison SL, Han G, Elenwa F et al (2022) Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma? Cancer 128:1418–1428. https://doi.org/10.1002/cncr.34013CrossRefPubMed

Kluger HM, Zito CR, Barr ML et al (2015) Characterization of PD-L1 expression and associated T‑cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 21:3052–3060. https://doi.org/10.1158/1078-0432.CCR-14-3073CrossRefPubMedPubMedCentral

Madore J, Vilain RE, Menzies AM et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28:245–253. https://doi.org/10.1111/pcmr.12340CrossRefPubMed

Eriksson H, Frohm-Nilsson M, Jaras J et al (2015) Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study. Br J Dermatol 172:175–186. https://doi.org/10.1111/bjd.13171CrossRefPubMed

Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205CrossRefPubMed

Inozume T, Yaguchi T, Furuta J et al (2016) Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase. J Invest Dermatol 136:255–263. https://doi.org/10.1038/JID.2015.404CrossRefPubMed

10.

Piras F, Colombari R, Minerba L et al (2005) The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104:1246–1254. https://doi.org/10.1002/cncr.21283CrossRefPubMed

11.

Maibach F, Sadozai H, Seyed Jafari SM et al (2020) Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol 11:2105. https://doi.org/10.3389/fimmu.2020.02105CrossRefPubMedPubMedCentral

12.

Jensen TO, Schmidt H, Moller HJ et al (2012) Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 118:2476–2485. https://doi.org/10.1002/cncr.26511CrossRefPubMed

13.

Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-gamma-related mRNA profile predicts clinical response to PD‑1 blockade. J Clin Invest 127:2930–2940. https://doi.org/10.1172/JCI91190CrossRefPubMedPubMedCentral

14.

Sade-Feldman M, Yizhak K, Bjorgaard SL et al (2018) Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175:998–1013.e20. https://doi.org/10.1016/j.cell.2018.10.038CrossRefPubMedPubMedCentral

15.

Kallies A, Zehn D, Utzschneider DT (2020) Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol 20:128–136. https://doi.org/10.1038/s41577-019-0223-7CrossRefPubMed

16.

Scott AC, Dundar F, Zumbo P et al (2019) TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571:270–274. https://doi.org/10.1038/s41586-019-1324-yCrossRefPubMedPubMedCentral

17.

Krishna S, Lowery FJ, Copeland AR et al (2020) Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370:1328–1334. https://doi.org/10.1126/science.abb9847CrossRefPubMedPubMedCentral

18.

Jameson SC, Masopust D (2018) Understanding subset diversity in T cell memory. Immunity 48:214–226. https://doi.org/10.1016/j.immuni.2018.02.010CrossRefPubMedPubMedCentral

19.

Beumer-Chuwonpad A, Taggenbrock R, Ngo TA et al (2021) The potential of tissue-resident memory T cells for adoptive immunotherapy against. Cancer Cells. https://doi.org/10.3390/cells10092234CrossRef

20.

Boddupalli CS, Bar N, Kadaveru K et al (2016) Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight 1:e88955. https://doi.org/10.1172/jci.insight.88955CrossRefPubMedPubMedCentral

21.

Smazynski J, Webb JR (2018) Resident memory-like tumor-infiltrating lymphocytes (TILRM): latest players in the immuno-oncology repertoire. Front Immunol 9:1741. https://doi.org/10.3389/fimmu.2018.01741CrossRefPubMedPubMedCentral

22.

Han J, Zhao Y, Shirai K et al (2021) Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat Cancer 2:300–311. https://doi.org/10.1038/s43018-021-00180-1CrossRefPubMedPubMedCentral

23.

Oliveira G, Stromhaug K, Klaeger S et al (2021) Phenotype, specificity and avidity of antitumour CD8(+) T cells in melanoma. Nature 596:119–125. https://doi.org/10.1038/s41586-021-03704-yCrossRefPubMedPubMedCentral

24.

Gokuldass A, Draghi A, Papp K et al (2020) Qualitative analysis of tumor-infiltrating lymphocytes across human tumor types reveals a higher proportion of bystander CD8(+) T cells in non-melanoma cancers compared to melanoma. Cancers (Basel). https://doi.org/10.3390/cancers12113344CrossRefPubMed

25.

Tietze JK, Wilkins DE, Sckisel GD et al (2012) Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T‑cell responses after cytokine-based cancer immunotherapy. Blood 119:3073–3083. https://doi.org/10.1182/blood-2011-07-369736CrossRefPubMedPubMedCentral

26.

Svane IM, Verdegaal EM (2014) Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Cancer Immunol Immunother 63:1081–1091. https://doi.org/10.1007/s00262-014-1580-5CrossRefPubMed

27.

Hunder NN, Wallen H, Cao J et al (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO‑1. N Engl J Med 358:2698–2703. https://doi.org/10.1056/NEJMoa0800251CrossRefPubMedPubMedCentral

28.

Kakavand H, Vilain RE, Wilmott JS et al (2015) Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 28:1535–1544. https://doi.org/10.1038/modpathol.2015.110CrossRefPubMed

29.

Erdag G, Schaefer JT, Smolkin ME et al (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72:1070–1080. https://doi.org/10.1158/0008-5472.CAN-11-3218CrossRefPubMedPubMedCentral

30.

Taramelli D, Fossati G, Mazzocchi A et al (1986) Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res 46:433–439PubMed

31.

Martins I, Sylla K, Deshayes F et al (2009) Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis. Melanoma Res 19:226–237. https://doi.org/10.1097/CMR.0b013e32832e0bc3CrossRefPubMed

32.

Chen YY, Chang WA, Lin ES et al (2019) Expressions of HLA class II genes in cutaneous melanoma were associated with clinical outcome: bioinformatics approaches and systematic analysis of public microarray and RNA-seq datasets. Diagnostics (Basel). https://doi.org/10.3390/diagnostics9020059CrossRefPubMedPubMedCentral

33.

Johnson DB, Estrada MV, Salgado R et al (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7:10582. https://doi.org/10.1038/ncomms10582CrossRefPubMedPubMedCentral

34.

Kim HJ, Cantor H (2014) CD4 T‑cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2:91–98. https://doi.org/10.1158/2326-6066.CIR-13-0216CrossRefPubMed

35.

Purwar R, Schlapbach C, Xiao S et al (2012) Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 18:1248–1253. https://doi.org/10.1038/nm.2856CrossRefPubMedPubMedCentral

36.

Togashi Y, Shitara K, Nishikawa H (2019) Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. Nat Rev Clin Oncol 16:356–371. https://doi.org/10.1038/s41571-019-0175-7CrossRefPubMed

37.

Fu Q, Chen N, Ge C et al (2019) Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. OncoImmunology 8:1593806. https://doi.org/10.1080/2162402X.2019.1593806CrossRefPubMedPubMedCentral

38.

Huang L, Guo Y, Liu S et al (2021) Targeting regulatory T cells for immunotherapy in melanoma. Mol Biomed 2:11. https://doi.org/10.1186/s43556-021-00038-zCrossRefPubMedPubMedCentral

39.

Tietze JK, Angelova D, Heppt MV et al (2017) Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy. Exp Dermatol 26:622–629. https://doi.org/10.1111/exd.13263CrossRefPubMed

40.

Long EO, Kim HS, Liu D et al (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31:227–258. https://doi.org/10.1146/annurev-immunol-020711-075005CrossRefPubMed

41.

Huntington ND, Cursons J, Rautela J (2020) The cancer-natural killer cell immunity cycle. Nat Rev Cancer 20:437–454. https://doi.org/10.1038/s41568-020-0272-zCrossRefPubMed

42.

Cristiani CM, Garofalo C, Passacatini LC et al (2020) New avenues for melanoma immunotherapy: natural killer cells? Scand J Immunol 91:e12861. https://doi.org/10.1111/sji.12861CrossRefPubMed

43.

Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M et al (2019) A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res 7:1162–1174. https://doi.org/10.1158/2326-6066.CIR-18-0500CrossRefPubMed

44.

Kuske M, Haist M, Jung T et al (2022) Immunomodulatory properties of immune checkpoint inhibitors-more than boosting T‑cell responses? Cancers (Basel). https://doi.org/10.3390/cancers14071710CrossRefPubMed

45.

Marin ND, Krasnick BA, Becker-Hapak M et al (2021) Memory-like differentiation enhances NK cell responses to melanoma. Clin Cancer Res 27:4859–4869. https://doi.org/10.1158/1078-0432.CCR-21-0851CrossRefPubMedPubMedCentral

46.

Wong PF, Wei W, Smithy JW et al (2019) Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma. Clin Cancer Res 25:2442–2449. https://doi.org/10.1158/1078-0432.CCR-18-2652CrossRefPubMedPubMedCentral

47.

Spitzer MH, Carmi Y, Reticker-Flynn NE et al (2017) Systemic immunity is required for effective cancer immunotherapy. Cell 168:487–502.e15. https://doi.org/10.1016/j.cell.2016.12.022CrossRefPubMedPubMedCentral

48.

Borgers JSW, Haanen J (2021) Cellular therapy and cytokine treatments for melanoma. Hematol Oncol Clin North Am 35:129–144. https://doi.org/10.1016/j.hoc.2020.08.014CrossRefPubMed

49.

Edwards J, Wilmott JS, Madore J et al (2018) CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD‑1 treatment. Clin Cancer Res 24:3036–3045. https://doi.org/10.1158/1078-0432.CCR-17-2257CrossRefPubMed

50.

van Vliet AA, Georgoudaki AM, Raimo M et al (2021) Adoptive NK cell therapy: a promising treatment prospect for metastatic melanoma. Cancers (Basel). https://doi.org/10.3390/cancers13184722CrossRefPubMed

51.

Mihm MC Jr., Mule JJ (2015) Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response. Cancer Immunol Res 3:827–835. https://doi.org/10.1158/2326-6066.CIR-15-0143CrossRefPubMedPubMedCentral

Titel: Tumorinfiltrierende T-Zellen und natürliche Killerzellen im Melanom
verfasst von: Prof. Dr. Julia K. Tietze
Publikationsdatum: 18.11.2022
Verlag: Springer Medizin
Schlagwörter: Melanom
Melanom
Erschienen in: Die Dermatologie / Ausgabe 12/2022
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI: https://doi.org/10.1007/s00105-022-05076-4

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Tumorinfiltrierende T-Zellen und natürliche Killerzellen im Melanom

Zusammenfassung

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Kognitive Funktionsstörungen beim metastasiertem Melanom

Immunbiologie des Melanoms

Warum sind diese palmaren Papeln ein Warnzeichen?

Beurteilung einer E‑Learning-Plattform für Dermatochirurgie

Das therapeutische Potenzial von Makrophagen im Melanom

Bullöse Arzneimittelreaktion nach Gabe von Pembrolizumab

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie